Paxman (OM:PAX) Profit Turn Sharpens Focus On Reimbursement Growth

Paxman stock closed at SEK55.0 on 21 August, capping a strong run over the past month. Yet the real story sits in the earnings rather than the chart. Q2 group revenue reached about SEK107.6m and the company reported a profit of SEK2.6m of net income from ongoing operations. That shift from loss making into the black is the single number long term holders will care about.

Short term traders are reacting to momentum. Longer term investors are now asking whether this first profitable quarter can anchor the multi year growth and valuation case already built into forecasts.

Impressed that Paxman has moved into profit but want more stocks that already pair consistent earnings with stronger balance sheets? Check out the list of solid balance sheet and fundamentals stocks (427 results).

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs Q2 2025: SEK107.645m vs SEK74.858m (up about 44%)
• Net Income from Continuing Operations, Q2 2026 vs Q2 2025: profit of SEK2.563m vs loss of SEK3.118m (swing into profit)
• Basic EPS, Q2 2026 vs Q2 2025: not disclosed for Q2 2026 vs loss of SEK0.140463 per share in Q2 2025 (EPS trend not directly comparable)
• Trailing 12 Month Revenue, TTM to Q2 2026 vs TTM to Q2 2025: SEK364.856m vs SEK261.516m (up about 40%)

Prefer visual charts instead of another dense wall of numbers and earnings tables? Get a clear view of Paxman’s full financial picture, with an easy-to-scan focus on its valuation, in the company report for Paxman.

Paxman bull case rides on utilization milestones

Bulls argue that Paxman is turning its installed base and reimbursement gains into a high quality, recurring earnings engine. Q2 revenue of about SEK107.6m with positive net income from ongoing operations and EBITDA of about SEK14m are important proof points that scale is beginning to support profitability rather than just growth for growth’s sake. The insurance based billing model is central to this narrative. IBBM revenue grew about 110% year on year and IBBM sites are treating roughly 3.4 to 8.6 patients per system each quarter compared with about 1.6 to 3.1 for self pay. That directly supports the claim that reimbursement can lift utilization and margins. The 190 system order book, including 80 in the U.S., also lines up with the view that the installed base is still expanding, not just sweating existing assets.

Bear case focuses on CIPN delays and cost pressure

Bearish arguments focus on regulatory friction around the neuropathy device, execution risk in reimbursement and rising costs that could cap margins. The shift from an FDA 510(k) route to a De Novo submission is a clear milestone missed relative to earlier expectations for a smoother path. Management now talks about an 8 to 12 month review cycle and points to possible stop start interactions with the regulator, which fits concerns about timing risk and additional evidence requests. Operating expenses were elevated in Q2 from exhibitions, R&D, legal work, personnel and Dignitana integration, while CIPN commercialization costs pull adjusted EBITDA margin down from about 18.5% to 13%. That supports the view that integration and development spending can weigh on earnings if utilization and the IBBM rollout do not keep pace.

Compare Paxman’s push toward recurring IBBM revenue and CIPN optionality with what the street is actually pricing in. See the consensus price target analysis for Paxman to check whether analysts think this SEK55.0 share price already bakes in the story or still leaves room for a different outcome.

Level Up Your Investing With Simply Wall St

If Paxman’s first profitable quarter has your attention, register for free with Simply Wall St and add it to a Watchlist so you can track the share price against fair value and watch how the story develops. When you decide to take a position, use the Portfolio Command Center to cut through noise and focus on the key updates that matter to your holdings. For a broader perspective on Paxman and other stocks, tap into shared research and sentiment through the Community. This can help you identify potential catalysts and risks early so you can stay ahead of the market instead of reacting to it late.

Seeking Alternatives Beyond Paxman Stock

Fresh ideas often move first when momentum builds and early data is still under the radar for now. Scan these focused stock lists before the crowd reacts and act now.

• Track resilient cash generators and stress test your watchlist against a curated list of solid balance sheet and fundamentals stocks (427 results) before prices start flying on the next bout of risk appetite.
• Spot early breakout potential in smaller companies by running through 219 elite penny stocks with strong financials while they are still dropping hints in the numbers rather than in front-page headlines.
• Position ahead of the next AI hardware and data boom by reviewing 55 AI infrastructure stocks before capital floods in and the easy entry points are gone.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com